Genomic Health (GHDX) Named Top Small Cap Pick at Leerink Partners

Leerink Partners analyst, Dan Leonard, highlighted Genomic Health (NASDAQ: GHDX) as his top small cap pick for 2016 with the expectation that revenue acceleration could lead to multiple expansion based on the company’s invasive breast cancer testing franchise.

Positive early results from the prospective Trial Assigning Individualized Options for Treatment (TAILORx) study could enhance clinician interest in GHDX’s core Oncotype Dx test for invasive breast cancer (~95% of revs). Even absent a dream scenario, TAILORx could drive U.S. invasive breast cancer volume growth to mid-single digits, up from low single-digit levels GHDX had experienced prior to Q3 2015.

No change to Outperform rating or price target of $38.

For an analyst ratings summary and ratings history on Genomic Health Inc. click here. For more ratings news on Genomic Health Inc. click here.

Shares of Genomic Health Inc. closed at $30.00 yesterday.

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• AvidBank Holdings Inc. (AVBH) PT Lowered to $23 at Piper Sandler
• Westamerica Bancorp (WABC) PT Lowered to $50 at Piper Sandler